Printer Friendly

NEW BREAST IMAGING BREAKTHROUGH CLEARED FOR MARKETING BY FDA

 DANBURY, Conn., Nov. 25 ~PRNewswire~ -- LORAD Corp., the leading U.S. manufacturer of breast imaging and biopsy equipment, today announced FDA clearance to market the LORAD DSM(TM) Digital Imaging System. This revolutionary, cost-saving technology reduces radiation dose, allows the physician to enhance and optimize the mammography image, and significantly reduces procedure time for women requiring closer scrutiny of a suspicious lesion.
 For women undergoing conventional surgical biopsy, the LORAD DSM(TM) Digital Imaging System can be used with the LORAD M-III mammography system for fast and accurate pre-surgical needle localization. For women undergoing a less invasive biopsy with the LORAD StereoGuide(TM) stereotactic needle core biopsy system, use of the DSM(TM) Digital Imaging System reduces overall procedure time from approximately one hour to only 25 minutes, resulting in significant cost-savings.
 "Digital imaging revolutionizes the cost-effectiveness of the (stereotactic biopsy) procedure," said David Dershaw, M.D., director of Breast Imaging at Memorial Sloan-Kettering Cancer Center in New York.
 The new technology creates an image on a computer screen within seconds of taking an x-ray, eliminating the time required for film development. Near real-time imaging also provides dynamic digital information which allows the physician to manipulate the data to visualize the optimum image and accurately pinpoint the ideal target for breast biopsy sampling.
 The LORAD DSM(TM) camera is interchangeable between two LORAD systems: StereoGuide(TM) stereotactic prone breast needle biopsy system for fine needle or core tissue sampling and the M-III mammography system for orthagonal needle localization. The DSM(TM) allows selection of two modes: high resolution and high sensitivity so that maximum information can be acquired at the lowest dose.
 LORAD Corp. has led an active research project in digital breast imaging for over four years. The LORAD DSM(TM) uses a 1024 high sensitivity chip as part of a special CCD camera designed and manufactured by LORAD. Using reflective intensification and artifact- free, precision lens coupling, the digital imaging design is homeostatic and photon efficient. Images are acquired and displayed in only three to six seconds. Spatial resolution is 10 lp~mm with 14 bit contrast resolution using a 50 x 50 cm active viewing area.
 "LORAD is pleased to introduce this revolutionary technology to women and their physicians. This is our latest breakthrough in bringing safe, accurate, state-of-the-art breast imaging equipment to market," said Hal Kirshner, LORAD president. "We also want to assure women and their health-care providers that the DSM(TM), as with all LORAD products, meets and exceeds the American College of Radiology's guidelines for mammography quality standards."
 The pioneer in breast health, LORAD Corp. is the largest U.S. supplier of state-of-the-art imaging systems for early breast cancer detection. The company has more than 2500 systems installed worldwide and a network of more than 75 dealers and distributors in over 30 countries. LORAD, recently acquired by ThermoTrex Corp. (AMEX: TKN), has its world headquarters, manufacturing and research and development facilities in Danbury, with additional research facilities in Hartford, Conn.
 The added resources of ThermoTrex and its parent, ThermoElectron, insure a continued evolution of new state-of-the-art imaging products with the financial and technical resources of a well-respected, billion dollar company. LORAD will continue to translate the advanced technologies jointly developed with ThermoTrex into additional medical imaging products which will surpass today's capabilities.
 -0- 11~25~92
 ~NOTE TO CHICAGO & MEDICAL EDITORS: The DSM(TM) system will be on display Nov. 29-Dec. 3 at the Radiological Society of North America meeting in McCormick Place East, LORAD booth no. 1115. LORAD will also be holding a press conference on Wednesday, Dec. 2, 2 p.m. in the RSNA News Room. At RSNA call the Sheraton Chicago 312-464-1000~
 ~CONTACT: Alison Bender Kellner or Brenda Williams of Dorf & Stanton Communications, 800-327-4442, or 203-327-3555, for LORAD~
 (TKN)


CO: LORAD Corp.; ThermoTrex Corp. ST: Connecticut IN: MTC SU:

PK-TM -- SF001 -- 1344 11~25~92 07:00 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 25, 1992
Words:647
Previous Article:VISNEWS BECOMES REUTERS TELEVISION
Next Article:SPECTRUM HOLOBYTE ENTERS THE VIDEO-GAME MARKET WITH WORDTRIS FOR SNES AND GAMEBOY
Topics:


Related Articles
FDA ADVISORY PANEL UNANIMOUSLY RECOMMENDS APPROVAL FOR ATL ULTRASOUND
IMMUNOMEDICS' CEA-SCAN DETECTS PRIMARY AND METASTATIC BREAST CANCER
Advanced Mammography Systems, Inc. Names Ruder Finn as Public Relations Agency
Imaging Diagnostic obtains breast imaging patent.
CADx Systems, Inc. Receives FDA Approval for Digital CAD With Fischer Imaging Full Field Digital Mammography Products.
ICAD AND FISCHER IMAGING FORM DISTRIBUTION AGREEMENT.
ICAD/FISCHER SIGN EXPANDED DEVELOPMENT/DISTRIBUTION PACT.
Applied Imaging Announces FDA Clearances to Market Breast Cancer Assessment Applications.
iCAD and Fischer Imaging Announce Expansion of Development and Distribution Relationship; iCAD Announces New Product for Mixed Digital and Film...
FDA Clears Use of Fischer MammoTest Breast Biopsy System as Platform for Interstitial Breast Brachytherapy.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters